SS-31 / Elamipretide
Mitochondria-targeted peptide. The specific medicine Forzinity has a US indication in Barth syndrome.
Search names: Elamipretide, SS31
Evidence
Medicine data · specific indication
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
Statistics reference: About 3–4 hours
Human information in catalogueContext and sources for the statistics reference
Terminal plasma half-life in humans; distinct from residence within mitochondria.
About 3–4 hours · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · SS-31 (Elamipretide) ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Adverse effects are not fully mapped in this entry. Consult the sources for the specific compound and use.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Study / medicine dataFORZINITY · prescribing information↗Find researchPubMed · SS-31 / Elamipretide↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.